After protracted haggling, Vertex Pharmaceuticals struck a five-year deal with the Scottish government to provide its cystic fibrosis treatments at a “confidential discount,” a notable win for the drug maker as it battles with several countries over providing coverage.

The move comes one month after the Scottish Medicines Consortium had recommended the National Health Service in Scotland should not cover the Orkambi and Symkevi medicines, because Vertex failed to present a “sufficiently robust” clinical and economic analysis to warrant the cost. The treatments may be suitable for about 400 of the 900 people in Scotland who have cystic fibrosis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy